Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20516320 | 1.00 | KMT2A (0.43) | KMT2ATSHRHTR2AHTR2CHTR2B | |
| SCHEMBL23849532 | 0.86 | AAK1 (0.42) | AAK1LMNAATMSMN1; SMN2 | |
| SCHEMBL29512402 | 0.86 | AAK1 (0.42) | AAK1LMNAATMSMN1; SMN2 | |
| SCHEMBL23849531 | 0.86 | AAK1 (0.42) | AAK1LMNAATMSMN1; SMN2 | |
| SCHEMBL23927017 | 0.81 | XDH (0.42) | AAK1XDH | |
| SCHEMBL11190342 | 0.80 | AAK1 (0.39) | TSHRHTR2AHTR2CHTR2BAAK1 | |
| SCHEMBL11297323 | 0.80 | KMT2A (0.49) | KMT2ATSHRHTR2AHTR2CHTR2B | |
| SCHEMBL233034 | 0.78 | TDP1 (0.56) | KMT2ATSHRHTR2AHTR2CHTR2B | |
| SCHEMBL20516276 | 0.78 | AAK1 (0.40) | AAK1SMN1; SMN2 | |
| SCHEMBL20516274 | 0.78 | AAK1 (0.40) | AAK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110799190-B | Heterocyclic compounds | 卡都瑞恩医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-113365632-B | Aminopyrimidine compounds | 卡都瑞恩医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3856188-B1 | AMINOPYRIMIDINE COMPOUND | CARDURION PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| CN-113365632-A | Aminopyrimidine compounds | 卡都瑞恩医药有限责任公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3856188-A1 | AMINOPYRIMIDINE COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | CARDURION PHARMACEUTICALS, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| WO-2020068854-A1 | AMINOPYRIMIDINE COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020068846-A1 | HETEROCYCLIC COMPOUND | HETEROCYCLIC COMPOUND (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095240-A1 | AMINOPYRIMIDINE COMPOUND | CARDURION PHARMACEUTICALS, LLC | 2020-03-26 | — | — | US | disclosed |
| CN-110799190-A | Heterocyclic compounds | 卡都瑞恩医药有限责任公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-3600327-A1 | HETEROCYCLIC COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183112-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | KMT2A 653/4885TSHR 1038/4885HTR2A 807/4885 |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CALM1, CAMK2B, CAMK2G | KMT2A 1477/4885TSHR 1125/4885HTR2A 2381/4885 |
| US-20200095240-A1 | AMINOPYRIMIDINE COMPOUND | CALM1, CAMK4, CAMK2B | KMT2A 1599/4885TSHR 2471/4885HTR2A 2783/4885 |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | KMT2A 653/4885TSHR 1038/4885HTR2A 807/4885 |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | TNNI3, CALM1, CAMK2G | KMT2A 653/4885TSHR 1038/4885HTR2A 807/4885 |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CAMK2B, RYR2, CAMK2A | KMT2A 2261/4885TSHR 885/4885HTR2A 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.